22
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Photodynamic Therapy Activity of New Porphyrin-Xylan-Coated Silica Nanoparticles in Human Colorectal Cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Photodynamic therapy (PDT) using porphyrins has been approved for treatment of several solid tumors due to the generation of cytotoxic reactive oxygen species (ROS). However, low physiological solubility and lack of selectivity towards tumor sites are the main limitations of their clinical use. Nanoparticles are able to spontaneously accumulate in solid tumors through an enhanced permeability and retention (EPR) effect due to leaky vasculature, poor lymphatic drainage, and increased vessel permeability. Herein, we proved the added value of nanoparticle vectorization on anticancer efficacy and tumor-targeting by 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH). Using 80 nm silica nanoparticles (SNPs) coated with xylan-TPPOH conjugate (TPPOH-X), we first showed very significant phototoxic effects of TPPOH-X SNPs mediated by post-PDT ROS generation and stronger cell uptake in human colorectal cancer cell lines compared to free TPPOH. Additionally, we demonstrated apoptotic cell death induced by TPPOH-X SNPs-PDT and the interest of autophagy inhibition to increase anticancer efficacy. Finally, we highlighted in vivo, without toxicity, elevated anticancer efficacy of TPPOH-X SNPs through improvement of tumor-targeting compared to a free TPPOH protocol. Our work demonstrated for the first time the strong anticancer efficacy of TPPOH in vitro and in vivo and the merit of SNPs vectorization.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Photodynamic therapy – mechanisms, photosensitizers and combinations

          Photodynamic therapy (PDT) is a modern and non-invasive form of therapy, used in the treatment of non-oncological diseases as well as cancers of various types and locations. It is based on the local or systemic application of a photosensitive compound - the photosensitizer, which is accumulated in pathological tissues. The photosensitizer molecules absorb the light of the appropriate wavelength, initiating the activation processes leading to the selective destruction of the inappropriate cells. The photocytotoxic reactions occur only within the pathological tissues, in the area of photosensitizer distribution, enabling selective destruction. Over the last decade, a significant acceleration in the development of nanotechnology has been observed. The combination of photosensitizers with nanomaterials can improve the photodynamic therapy efficiency and eliminate its side effects as well. The use of nanoparticles enables achievement a targeted method which is focused on specific receptors, and, as a result, increases the selectivity of the photodynamic therapy. The object of this review is the anticancer application of PDT, its advantages and possible modifications to potentiate its effects.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals.

            Mesoporous silica nanoparticles (MSNs) are a promising material for drug delivery. In this Full Paper, MSNs are first shown to be well tolerated, as demonstrated by serological, hematological, and histopathological examinations of blood samples and mouse tissues after MSN injection. Biodistribution studies using human cancer xenografts are carried out with in vivo imaging and fluorescent microscopy imaging, as well as with inductively coupled plasma mass spectroscopy. The results show that MSNs preferentially accumulate in tumors. Finally, the drug-delivery capability of MSNs is demonstrated by following tumor growth in mice treated with camptothecin-loaded MSNs. These results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles.

              The remarkable progress of nanotechnology and its application in biomedicine have greatly expanded the ranges and types of biomaterials from traditional organic material-based nanoparticles (NPs) to inorganic biomaterials or organic/inorganic hybrid nanocomposites due to the unprecedented advantages of the engineered inorganic material-based NPs. Colloidal mesoporous silica NPs (MSNs), one of the most representative and well-established inorganic materials, have been promoted into biology and medicine, and shifted from extensive in vitro research towards preliminary in vivo assays in small-animal disease models. In this comprehensive review, the recent progresses in chemical design and engineering of MSNs-based biomaterials for in vivo biomedical applications has been detailed and overviewed. Due to the intrinsic structural characteristics of elaborately designed MSNs such as large surface area, high pore volume and easy chemical functionalization, they have been extensively investigated for therapeutic, diagnostic and theranostic (concurrent diagnosis and therapy) purposes, especially in oncology. Systematic in vivo bio-safety evaluations of MSNs have revealed the evidences that the in vivo bio-behaviors of MSNs are strongly related to their preparation prodecures, particle sizes, geometries, surface chemistries, dosing parameters and even administration routes. In vivo pharmacokinetics and pharmacodynamics further demonstrated the effectiveness of MSNs as the passively and/or actively targeted drug delivery systems (DDSs) for cancer chemotherapy. Especially, the advance of nano-synthetic chemistry enables the production of composite MSNs for advanced in vivo therapeutic purposes such as gene delivery, stimuli-responsive drug release, photothermal therapy, photodynamic therapy, ultrasound therapy, or anti-bacteria in tissue engineering, or as the contrast agents for biological and diagnostic imaging. Additionally, the critical issues and potential challenges related to the chemical design/synthesis of MSNs-based "magic bullet" by advanced nano-synthetic chemistry and in vivo evaluation have been discussed to highlight the issues scientists face in promoting the translation of MSNs-based DDSs into clinical trials. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
                Bookmark

                Author and article information

                Journal
                Cancers (Basel)
                Cancers (Basel)
                cancers
                Cancers
                MDPI
                2072-6694
                30 September 2019
                October 2019
                : 11
                : 10
                : 1474
                Affiliations
                [1 ]Laboratoire PEIRENE EA 7500, Faculté de Pharmacie, Université de Limoges 2, Rue du Docteur Raymond Marcland, 87025 Limoges Cedex, France; ludovic.bretin@ 123456unilim.fr (L.B.); aline.pinon@ 123456unilim.fr (A.P.); david.leger@ 123456unilim.fr (D.Y.L.)
                [2 ]Laboratoire PEIRENE EA 7500, Faculté des Sciences & Techniques, Université de Limoges 123, Avenue Albert Thomas, 87060 Limoges Cedex, France; soukaina.bouramtane@ 123456unilim.fr (S.B.); frederique.bregier@ 123456unilim.fr (F.B.); vincent.sol@ 123456unilim.fr (V.S.); vincent.chaleix@ 123456unilim.fr (V.C.)
                [3 ]BISCEm Pôle Cytométrie en flux/Microscopie, Université de Limoges 2, Rue du Docteur Raymond Marcland, 87025 Limoges Cedex, France; catherine.ouk@ 123456unilim.fr (C.O.); claire.carrion@ 123456unilim.fr (C.C.)
                [4 ]Service d’Anatomie Pathologique, Centre Hospitalier Universitaire de Limoges 2, Avenue Martin Luther King, 87042 Limoges Cedex, France; laurence.richard@ 123456unilim.fr (L.R.); alain.chaunavel@ 123456chu-limoges.fr (A.C.)
                [5 ]Laboratoire Bio EM XLIM UMR CNRS 7252, Faculté de Médecine, Université de Limoges 2, Rue du Docteur Raymond Marcland, 87025 Limoges Cedex, France; marie-laure.perrin@ 123456unilim.fr
                Author notes
                Author information
                https://orcid.org/0000-0002-2949-0512
                https://orcid.org/0000-0003-2419-8974
                https://orcid.org/0000-0002-9880-7616
                https://orcid.org/0000-0003-0175-0156
                https://orcid.org/0000-0002-5324-3095
                https://orcid.org/0000-0003-4148-2598
                Article
                cancers-11-01474
                10.3390/cancers11101474
                6826978
                31575052
                feaae70b-bbf8-46db-ae0b-a5f797b939ed
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 September 2019
                : 28 September 2019
                Categories
                Article

                anticancer drug,porphyrin,silica nanoparticles,drug delivery,photodynamic therapy

                Comments

                Comment on this article